Comparative Pharmacology
Head-to-head clinical analysis: PERPHENAZINE versus PROCHLORPERAZINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERPHENAZINE versus PROCHLORPERAZINE MALEATE.
PERPHENAZINE vs PROCHLORPERAZINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Perphenazine is a typical antipsychotic that exerts its effects by blocking postsynaptic dopamine D2 receptors in the brain, particularly in the mesolimbic pathway. It also has antagonistic activity at alpha-adrenergic, histaminergic, and muscarinic receptors.
Prochlorperazine is a phenothiazine antipsychotic that primarily antagonizes dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) and central nervous system. It also has anticholinergic and antiemetic effects through blockade of histamine H1 and muscarinic M1 receptors.
Oral: 4-16 mg 2-4 times daily; maximum 64 mg/day. Intramuscular: 5-10 mg every 6 hours; maximum 30 mg/day. Intravenous: 1-5 mg slow IV every 6 hours; maximum 10 mg/day.
5-10 mg orally 3-4 times daily; or 25 mg rectally twice daily; or 5-10 mg intramuscularly every 3-4 hours up to 40 mg/day; or 2.5-10 mg intravenously slowly at 2.5 mg/min, maximum 20 mg/day.
None Documented
None Documented
Clinical Note
moderatePerphenazine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Perphenazine is combined with Fluticasone propionate."
Clinical Note
moderatePerphenazine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Perphenazine."
Clinical Note
moderatePerphenazine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Perphenazine."
Clinical Note
moderatePerphenazine + Methylphenidate
The terminal elimination half-life of perphenazine is approximately 8–12 hours in adults with normal hepatic function. This supports twice-daily dosing for maintenance therapy. In elderly patients or those with hepatic impairment, half-life may be prolonged.
Terminal elimination half-life is approximately 6-8 hours in adults, but may extend up to 12-15 hours after chronic dosing or in hepatic impairment.
Perphenazine is extensively metabolized in the liver, primarily via CYP2D6, and eliminated predominantly as metabolites in urine (approximately 70%) and feces (about 30%). Less than 1% is excreted unchanged in urine.
Primarily renal (70-80% as metabolites, <1% unchanged); fecal/biliary excretion accounts for 20-30% via enterohepatic circulation.
Category A/B
Category A/B
Typical Antipsychotic
Typical Antipsychotic / Antiemetic
"The risk or severity of adverse effects can be increased when Perphenazine is combined with Methylphenidate."